Moreover, the selective COX-2 inhibitor compound SC-236 showed antitumor activity through the blocking of tumor promotor-induced activator protein-1 (AP1) activation as a result of the suppression of JNK expression and was used to treat hepatocellular cancer in conjunction with doxorubicin [30]. The gene discussed is MAPK8; the disease is hepatocellular carcinoma.